Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer Academic Article uri icon

Overview

MeSH Major

  • Benzamides
  • Carcinoma, Non-Small-Cell Lung
  • Indazoles
  • Lung Neoplasms
  • Receptor, trkA

abstract

  • Entrectinib demonstrated significant anti-tumor activity in a patient with NSCLC harboring an SQSTM1-NTRK1 gene rearrangement, indicating that entrectinib may be an effective therapy for tumors with NTRK gene rearrangements, including those with central nervous system metastases.

publication date

  • January 2015

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4643748

Digital Object Identifier (DOI)

  • 10.1097/01.JTO.0000473485.38553.f0

PubMed ID

  • 26565381

Additional Document Info

start page

  • 1670

end page

  • 4

volume

  • 10

number

  • 12